Adam Simpson, PhD
Chief Executive Officer
Dr. Adam Simpson joined Dermelix from Dermavant Sciences, where he was integral in the early growth of the company while leading business development and medical affairs functions. Previously, Dr. Simpson was a member of the Roivant Sciences business development team, where he led the sourcing and acquisition of drug candidates across the therapeutic landscape. Dr. Simpson holds a B.A. in Chemistry with highest honors and highest distinction from the University of North Carolina at Chapel Hill, and a Ph.D. in Molecular Biophysics and Biochemistry from Yale University where he was an HHMI scholar.
Nick France, MBChB, BSc (Hons), MRCPCH
Chief Medical Officer
Dr. Nick France trained in pediatric medicine and pharmacology in the UK, He has worked extensively in global biopharma research and development for the past 10 years in both the USA and the UK, holding positions of increasing responsibility including senior leadership roles of several programs that have led to several drug approvals for rare disease therapies. He has worked at GlaxoSmithKline’s Rare Diseases Unit, CSL Behring, Strongbrige Biopharma and Roivant Sciences.
Dr. France received his medical degree from the University of Warwick Medical School, his undergraduate honors degree in pharmacology from Kings College London and undertook his medical training in major academic children’s hospitals in London. He holds Membership of the Royal College of Paediatrics and Child Health.
Katie St. Ledger, MS
Senior Director, Clinical Research
Katie St. Ledger MS, an expert in strategic clinical drug development and approvals, joined Dermelix from Axovant Sciences where she led several clinical development programs. Prior to Axovant, she was a Clinical Development Scientific Director at CSL Behring and a key leader in the clinical development group where she was instrumental in obtaining orphan drug designations and regulatory approvals of several rare disease drugs in multiple territories including the US and Europe.
Senior Director, Clinical Operations
Kristin Ingrassia has 17 years of industry experience in global clinical operations in all phases of drug development in various therapeutic areas including coagulation, oncology, transplant and infectious disease. Prior to joining Dermelix, she spent 6 years in rare disease clinical operations at CSL Behring leading clinical trial activities through BLA/MAA/PMDA filing and regulatory inspections that ultimately resulted in the global approval of a rare disease drug.
Younok Dumortier Shin, PhD, MBA
Vice President, CMC and Drug Supply
Dr. Younok Dumortier Shin has more than 20 years of experience in research, product development, manufacturing and supply. Through her tenures at GlaxoSmithKline, Bristol Myers Squibb, Janssen-Johnson and Johnson, and Allergan, with increasing responsibility including senior leadership roles, she helped launching various new products and expanding existing products globally. She loves science that transforms into a medicine that helps people’s lives, and continues to devote herself to be the link that makes it all possible. Dr. Shin holds a B.A.Sc. in Chemical Engineering from University of British Columbia, a Ph.D. in Chemical Engineering from McGill University, and a MBA from Babson College specialized in Entrepreneurship.